Pulse Tracker to Inform the Launch of New HIV Drugs in a Competitive Market

The client looked to ThinkGen to help identify the appropriate patient and use case to build HCP experience with these two HIV brands. As with any launch, monitoring adoption and use is critical, especially in the HIV space, as there are already many effective options available to treat HIV. There were competitive advantages to the client’s two drugs, particularly with growing clinical experience reports of a favorable tolerability profile vs. existing integrase STRs.

Additionally, the client wanted to monitor and more deeply understand HCP interaction with pharmaceutical reps, their beliefs about these two new drugs, and how the drugs would be used. Specifically, the client sought for ThinkGen to determine if the HCPs view their two drugs as a viable switch option from integrase inhibitors, and which of the two drugs they would prefer and why. The client also wanted to know if the HCPs would ever use either of their drugs as a first line treatment instead of the leading integrase inhibitor.